Unicycive Therapeutics Inc
NASDAQ:UNCY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Unicycive Therapeutics Inc
NASDAQ:UNCY
|
US |
|
E
|
Envela Corp
AMEX:ELA
|
US |
|
Z
|
Zhejiang Three Stars New Materials Co Ltd
SSE:603578
|
CN |
|
Healthcare Global Enterprises Ltd
NSE:HCG
|
IN |
|
T
|
Tialis Essential IT PLC
LSE:TIA
|
UK |
Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 9 full-time employees. The company went IPO on 2021-06-17. The firm is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively.
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 9 full-time employees. The company went IPO on 2021-06-17. The firm is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively.
